Gilead Sciences: Forget About Hepatitis C…Everyone Else Is
December 02, 2016 at 10:57 AM EST
After hosting a dinner with Gilead Sciences ( GILD ), Piper Jaffray's Joshua Schimmer and team contend that investor attention is finally beginning to turn away from hepatitis C. They explain:
